Skip to content

Expressive Writing in GVHD

Assessing the Impact of Expressive Writing as a Nonpharmacologic Therapeutic Intervention Within a New Support Group for Patients With Cutaneous Graft-versus-Host Disease (EXPRESS-C-GVHD): A Pilot Trial

Status
Terminated
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05694832
Acronym
EXPRESS-C-GVHD
Enrollment
3
Registered
2023-01-23
Start date
2023-01-21
Completion date
2024-05-24
Last updated
2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graft Versus Host Disease

Brief summary

Graft-versus-host-disease (GVHD) is a disease phenomenon that occurs when immune cells of the donor recognize and attack healthy tissue within the transplant recipient, or host. It is ultimately the result of the same immunological mechanisms that provide benefit to patients receiving hematopoietic stem cell transplantation (HSCT). In patients with hematologic malignancies, HSCT can be therapeutic, as donor T cells recognize and mount a response against cancerous cells. HSCT is also used in the setting of certain immunodeficiencies and inborn errors of metabolism for which therapeutic benefit is found in immunologic repletion. To our knowledge, support groups have yet to be investigated in academic literature as a nonpharmacologic, therapeutic intervention for cutaneous GVHD patients to improve their distress, systemic disease, and quality of life. Given the dearth of research on nonpharmacologic therapies for cutaneous GVHD that address quality of life impairments, we seek to characterize the effect of an expressive writing and peer helping intervention contextualized within the framework of a support group. The primary goal of this study is to provide preliminary efficacy data of expressive writing as an intervention in patients with cutaneous GVHD to trial.

Interventions

BEHAVIORALExpressive Writing

Creative writing, discussion and social support, in a group setting via videoconference

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must have an active or previously diagnosed chronic cutaneous graft-versus-host disease (cGVHD). * Patients must be age ≥18 years. * Patients must be able to write using a utensil and paper or be able to type. * Patients must have access to internet or cellular connectivity with sufficient bandwidth to participate in videoconferences (Zoom). * Patients should be able to and planning to attend all four live videoconferencing sessions for the support group via Zoom. * Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion criteria

* Patients with limited level of oral and written English.

Design outcomes

Primary

MeasureTime frameDescription
Change in Dermatology Life Quality Index scores4 weeksMeasured at baseline and post completion of the 4 week expressive writing sessions

Secondary

MeasureTime frameDescription
Change in Short Form-36 scores4 weeksMeasured at baseline and post completion of the 4 week expressive writing sessions

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026